Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities

Clin Infect Dis. 2018 May 2;66(10):1487-1491. doi: 10.1093/cid/ciy008.

Abstract

Although significant progress has been made, the latest data from low- and middle-income countries show substantial gaps in reaching the third "90%" (viral suppression) of the UNAIDS 90-90-90 goals, especially among vulnerable and key populations. This article discusses critical gaps and promising, evidence-based solutions. There is no simple and/or single approach to achieve the last 90%. This will require multifaceted, scalable strategies that engage people living with human immunodeficiency virus, motivate long-term treatment adherence, and are community-entrenched and ‑supported, cost-effective, and tailored to a wide range of global communities.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / economics
  • Anti-HIV Agents / therapeutic use*
  • Child
  • Developing Countries*
  • Drug Resistance, Viral
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / economics
  • HIV-1 / drug effects
  • Homosexuality, Male
  • Humans
  • Male
  • Medication Adherence
  • Point-of-Care Testing
  • Pregnancy
  • Pregnancy Complications, Infectious / prevention & control*
  • Viral Load

Substances

  • Anti-HIV Agents